Novartis

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

Goldman Sachs estimates that AI drug discovery and breakthroughs like gene editing will add 0.5% to 2.5% to the U.S. gross domestic product. McKinsey & Co. follows suit, noting AI could generate 30% efficiency gains and cost savings in the pharmaceutical sector and trigger financial gains of up to $110 billion annually.

Biotech company Immunai, which developed an AI-based immune system mapping technology for drug development, announces the appointment of Dr. Mikael Dolsten to its board of directors.

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

Beyond speed, AI has also helped reduce costs. Conventional methods required nearly $35,000 per genome analysis, but AI-driven models running on GPUs have lowered the cost to under $2,000, making high-quality genomic research more accessible.

We recently published a list of 35 Non-Tech AI Opportunities Amid DeepSeek Selloff. In this article, we are going to take a look at where IQVIA Holdings Inc. (NYSE:IQV) stands against other non-tech AI opportunities amid DeepSeek selloff.

"And we're not used to having somebody without a career at stake in the room at a senior level," said Hudson.

The Innovation Capability Centre plans to hire 750 professionals, including software engineers, data scientists, and cybersecurity experts, with a particular emphasis on AI-driven talent. According to Gabriele Ricci,